Ulcerative colitis is a long-term condition where the colonand rectum become inflamed. Smallulcers can develop onthe colons liningand can bleed and produce pus. The main symptoms of ulcerative colitis are recurring diarrhoea, which may contain blood, mucus or pus, stomach pain and increased stool frequency Continue reading →

Study design and patient population A single-center retrospective study design was used to investigate the follow-up of patients treated with IN between 2015 and 2020. Powdered IN (Fujian Province, China) was purchased from Uchidawakanyaku Ltd. (Tokyo, Japan) Continue reading →

Pfizers once-daily S1P receptor modulator Velsipity (etrasimod) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat moderately-to-severely active ulcerative colitis (UC). The drug has been concurrently recommended by the National Institute for Health and Care Excellence (NICE) for use in patients aged 16 years and older who have had an inadequate response, lost response or been intolerant to conventional therapy or biological treatment. Affecting approximately 300,000 people in the UK, UC is a chronic, immune-mediated condition where the colon and rectum become inflamed, causing symptoms such as frequent diarrhoea, bowel urgency, rectal bleeding, abdominal pain, fatigue, fever and anaemia. Continue reading →

Patients This was a retrospective study targeting patients with ICI-induced colitis who had undergone colonoscopy at the onset of the disease at Kyoto University Hospital, affiliated hospitals, and Kindai University Faculty of Medicine between April 2018 and April 2023. All but one patient (Case 1) was treated with only ICI treatment. ICI-induced colitis was defined as diarrhea or bloody stools following ICI administration and/or with histological evaluation [5]. Continue reading →

When I was a kid, I took lots of tripsto the bathroom. Continue reading →

NICE is the organisation that decides whether treatments should be available on the NHS in England. Wales and Northern Ireland usually follow NICE decisions too. In Scotland, these decisions are made by the Scottish Medicines Consortium (SMC). Continue reading →